Results 91 to 100 of about 51,268 (235)

The once-daily fixed-dose combination of olodaterol and tiotropium in the management of COPD : current evidence and future prospects [PDF]

, 2019
Long-acting bronchodilators are the cornerstone of pharmacologic treatment of chronic obstructive pulmonary disease (COPD). Spiolto (R) or Stiolto (R) is a fixed-dose combination (FDC) containing two long-acting bronchodilators, the long-acting ...
Brusselle, Guy, Derom, Eric, Joos, Guy
core   +1 more source

3,4‐Methylenedioxymethamphetamine (MDMA) does not induce robust psychomotor activation and 50‐kHz ultrasonic vocalisations in tryptophan hydroxylase 2 (Tph2)‐deficient rats lacking serotonin in the central nervous system

British Journal of Pharmacology, EarlyView.
Background and Purpose 3,4‐Methylenedioxymethamphetamine (MDMA), commonly known as ecstasy, is a psychostimulant with entactogenic properties and known to induce arousal and euphoria. As an amphetamine derivate, MDMA acts on the monoamine systems in the brain and stimulates release of dopamine (DA), noradrenaline (NA) and serotonin (5‐HT), yet their ...
Tianhua Wang, Rainer K. W. Schwarting, Markus Wöhr   +2 more
wiley   +1 more source

Simultaneous release of glutamate and acetylcholine from single magnocellular "cholinergic" basal forebrain neurons [PDF]

, 2006
Basal forebrain (BF) neurons provide the principal cholinergic drive to the hippocampus and cortex. Their degeneration is associated with the cognitive defects of Alzheimer's disease. Immunohistochemical studies suggest that some of these neurons contain
Abogadie, FC, Allen, TGJ, Brown, DA
core   +1 more source

Evaluation of preclinical antipsychotic models used to support first‐in‐human clinical trials

British Journal of Pharmacology, EarlyView.
Abstract Schizophrenia is regarded as a complex and heterogeneous psychiatric disorder, characterised by diverse symptoms and comorbidities, which complicate both clinical management and drug development. Current pharmacological treatment, primarily based on dopamine D2 receptor antagonism or partial agonism, which has not markedly progressed since the
Thi Viet Ha Nguyen, Declan P. McKernan, John P. Kelly   +2 more
wiley   +1 more source

Multiple Residues in the Second Extracellular Loop Are Critical for M3 Muscarinic Acetylcholine Receptor Activation [PDF]

, 2007
Recent studies suggest that the second extracellular loop (o2 loop) of bovine rhodopsin and other class I G protein-coupled receptors (GPCRs) targeted by biogenic amine ligands folds deeply into the transmembrane receptor core where the binding of cis ...
Kim, Soo-Kyung, Li, Bo, Scarselli, Marco, Wess, Jürgen   +3 more
core   +1 more source

Protectin D1 and maresin 1 attenuate airway hyperreactivity induced by IL‐13 in human isolated small bronchi

British Journal of Pharmacology, EarlyView.
Background and Purpose Interleukin (IL)‐13 is implicated in airway hyperreactivity (AHR), a key feature of asthma. We explored the potential anti‐AHR activity of selected specialised pro‐resolving mediators (SPMs) in IL‐13‐induced AHR models, using human bronchial smooth muscle cells (BSMCs) and human isolated bronchi.
Willem Abma, Sven‐Erik Dahlén, Craig E. Wheelock, Mikael Adner, Mamdoh Al‐Amerie, Erik Sachs, Kasra Vali Jalali, Leonardo De Maria, Henric Olsson, Jesper Säfholm   +9 more
wiley   +1 more source

Profile of a fixed-dose combination of tiotropium/olodaterol and its potential in the treatment of COPD

International Journal of COPD, 2015
Sanjeevan Muruganandan,1 Lata Jayaram2,3 1Department of Respiratory and Sleep Medicine, Austin Health, 2Department of Respiratory and Sleep Medicine, Western Health, 3University of Melbourne, Melbourne, Victoria, Australia Abstract: Chronic obstructive
Muruganandan S, Jayaram L
doaj  

Management of COPD in the UK primary-care setting : an analysis of real-life prescribing patterns [PDF]

, 2014
Peer reviewedPublisher ...
Ashton, Valerie L, Bichel, Katsiaryna, Brusselle, Guy, Gruffydd-Jones, Kevin, Hutton, Catherine, Jones, Rupert, Miravitlles, Marc, Price, David, Rossi, Andrea, Stewart, Rebecca, West, Daniel   +10 more
core   +6 more sources

Vesicular glutamate transporter VGLUT2 expression emerges in substantia nigra dopamine neurons in mouse models of parkinsonism in the absence of neurodegeneration

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Subsets of midbrain dopamine (DA) neurons express the vesicular glutamate transporter VGLUT2 and can release the excitatory neurotransmitter glutamate. VGLUT2+ DA neurons of the substantia nigra pars compacta (SNc) were shown to be more resistant to neurodegeneration in animal models of Parkinson's disease (PD ...
Sivakumar Srinivasan, Christian Pifl, Thomas Steinkellner   +2 more
wiley   +1 more source

A role for epithelium‐derived 6‐nitrodopamine on human ureter contractility

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose To investigate the basal release of 6‐nitrodopamine (6‐ND) from human isolated ureter and the role of this novel catecholamine in the ureter contractility. Experimental Approach Ureters from 67 brain‐dead organ donors (40 males and 27 females) were used during kidney transplantation procedures.
Wilmar Azal Neto, Denis Lima Oliveira, José Britto‐Júnior, Alex Henrique Miller, Flaviano Lorenzon, Felipe Fernandes Jacintho, Valéria Barbosa de Souza, Fernanda Viviane Mariano, André Almeida Schenka, Fabiola Zakia Mónica, Adriano Fregonesi, Edson Antunes, Gilberto De Nucci   +12 more
wiley   +1 more source